预约演示

PTC, after multiple FDA rejections, will try again with Translarna

2024-03-19

加速审批

PTC Therapeutics has suffered multiple rejections of its Duchenne muscular dystrophy drug at the FDA but will try for approval again after receiving "recent feedback" from the agency.

PTC Therapeutics PTCpite Translarna's troubled history at the FDA—and a reDuchenne muscular dystrophyEurope—PTC ThFDApeutics once again hopes to convince U.S. regulators of the value of its Duchenne muscular dystrophy (DMD) therapy.

Tuesday, the company revealed that it plans tFDAesubmit Translarna to the FDA for the treatPTC Therapeutics mutation DMD by the middle of the year. The decision is based on Duchenne muscular dystrophy (DMD) FDA rejections of the drug in 2016 and 2017.

In its first rejection of the drug, the FDA told the company the applicatiFDAwasn't sufficiently cononsense mutation DMD rejection, the agency raised flags about a lack of clinical evidence and other shortfaFDA in PTC's filing.

More recently, European regulators in JaFDAry issued a negative opinion on renewing the DMD drug's authorization nearly a decade after its debut there. That decision came after a negative recommendation in SeptembePTC023 and a multi-month appeal process.

At the time of the latest decision, PTC CEO Matthew Klein said the developments "will result in the withdrawal" of Translarna in Europe.

In deciding against renewing the druPTC PTC authorization, Europe's Committee for Medicinal Products for Human Use looked at Translarna’s data from the placebo-controlled Study 041, plus other trials. In Study 041, the PTC drug failed to meet statistical significance on its primary endpoint in a selected patient subgroup, but it did turn in "nominally statistically significant results on several key endpoints," the company argued.

The study's primary endpoint looked at changes from baseline in a six-minute walking distance test. Even as PTC stood behind the medicine, the European Medicines Agency stated bluntly that the study "failed to confirm Translarna's effectiveness."

After the Study 041 results dropped, the FDA told the company that the new trial doesn't provide enough evidPTCe of benefit to support a resubmEuropean Medicines AgencyC quarterly filing from last year. In response, PTC said it would request a meeting with the agency "to review the “totality of data collected to date."

On a recent conference call, Klein said tFDAcompany had a meeting scheduled for this month with the agency.PTC

Besides the Translarna development, PTC on Tuesday said it has submitted a biologics license application for Upstaza to treat aromatic L-amino acid decarboxylase deficiency to the FDA.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构